Trial
NCT03591380
CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
GlaxoSmithKline; American College of Surgeons
Condition
Kidney Transplantation
Intervention
Belimumab
Why stopped
Recruitment complications due to COVID-19
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-01-09